Moog Rainer
Transfus Apher Sci. 2019 Dec;58(6):102668. doi: 10.1016/j.transci.2019.102668. Epub 2019 Nov 2.
There is a demand for self-sufficiency of plasma from the government of the Federal Republic of Germany. To fulfill this, a number of efforts undertaken over the last years. This report describes the current status of the plasma supply in Germany. Data were retrieved from the Paul-Ehrlich-Institute which collects data on the collection and use of blood including plasma according to the German Transfusion Act. Collection of therapeutic plasma showed a slight decline since 2013 but a new peak was observed in 2017. Plasma for fractionation remained almost constant for the last years and about 2 million liters of plasma for fractionation are collected as source plasma. Manufacture of immunoglobulin is steadily increasing to treat patients with immunodeficiencies. Human plasma Factor VIII and IX are still used for treatment of haemophilia in the era of recombinant products. Import and export of plasma for fractionation ensure the supply of plasma derivatives. Targeted fibrinogen supplementation in combination with individualized patient blood management resulted in a decreased use of therapeutic plasma units.
德意志联邦共和国政府对血浆自给自足有需求。为实现这一目标，过去几年采取了多项举措。本报告描述了德国血浆供应的现状。数据取自保罗·埃利希研究所，该研究所根据德国输血法案收集有关包括血浆在内的血液采集和使用的数据。自2013年以来，治疗性血浆的采集略有下降，但在2017年观察到一个新的峰值。过去几年用于分馏的血浆几乎保持不变，约200万升用于分馏的血浆作为原料血浆被采集。免疫球蛋白的生产稳步增加，用于治疗免疫缺陷患者。在重组产品时代，人血浆因子VIII和IX仍用于治疗血友病。用于分馏的血浆的进出口确保了血浆衍生物的供应。与个体化患者血液管理相结合的靶向纤维蛋白原补充导致治疗性血浆单位的使用减少。
